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Edited by Hans-Dieter KlenkAbstract The spike (S) protein of severe acute respiratory syn-
drome coronavirus (SARS-CoV) is an important viral structural
protein. Based on bioinformatics analysis, 10 antigenic peptides
derived from the S protein sequence were selected and synthe-
sized. The antigenicity and immunoreactivity of all the peptides
were tested in vivo and in vitro. Four peptides (P6, P8, P9 and
P10) which contain B cell epitopes of the S protein were identi-
ﬁed, and P8 peptide was conﬁrmed in vivo to have a potential in
serological diagnosis. By using a syncytia formation model, we
tested the neutralization ability of all 10 peptides and their cor-
responding antibodies. It is interesting to ﬁnd that P8 and P9
peptides inhibited syncytia formation, suggesting that the P8
and P9 spanning regions may provide a good target for anti-
SARS-CoV drug design. Our data suggest that we have identi-
ﬁed peptides derived from the S protein of SARS-CoV, which
are useful for SARS treatment and diagnosis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Severe acute respiratory syndrome (SARS) is a serious epi-
demic infectious disease that occurred from November 2002
to September 2003 and reappeared in parts of China in 2004.
This devastating disease has a relatively high mortality [1].Abbreviations: SARS-CoV, severe acute respiratory syndrome-associ-
ated coronavirus; Abs, antibodies
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doi:10.1016/j.febslet.2005.02.070The SARS-associated coronavirus, named SARS-CoV, is
the pathogen of this disaster [2]. This new kind of coronavirus
is an enveloped and positive-stranded RNA (+RNA) virus,
with a single-stranded genome, which contains four structural
proteins, spike (S) protein, membrane (M) protein, small enve-
lope protein and nucleocapsid (N) protein [3].
The SARS-CoV spread quickly in China and many other
countries. Since there is no eﬀective method so far to prevent
and treat this disease, an accurate diagnostic method and an
eﬀective clinical anti-viral drug or vaccine are urgently needed.
The S protein of SARS-CoV is a good candidate for disease
diagnosis and vaccine design.
The S protein (gi: 30173397) consists of 1255 amino acids
and has several glycosylation sites. It is believed that the S pro-
tein has two domains, S1 and S2. S1 plays an important role in
virus binding to virus-receptor (ACE2) while S2 mediates the
fusion between the viral particle and its target cell [4,5].
According to our current work, we conﬁrmed that S protein
can be cleaved into two parts [5]. It is predicted that the S pro-
tein yields two fragments spanning residues from 1 to 667 (S1)
and 668 to 1255 (S2). So 10 peptide sequences (with 18–30 res-
idues in length) were selected from S protein (in which peptides
P1-8 are located in the S1 part and peptides P9-10 are located
in S2) based on a series of bioinformatics analysis [6,7].
The peptides then were used to immunize rabbits. The spec-
iﬁcity of antisera induced by peptides was analyzed by Western
blot with recombinant expressed S, S1 and S2 proteins as well
as the lysates of SARS-CoV infected Vero E6 cells. SARS pa-
tients sera were used to conﬁrm the speciﬁc immunoreactivity
of the selected peptides. The syncytia formation model was
used to evaluate the neutralization ability of the peptides and
their corresponding antibodies (Abs).
The data demonstrated that all 10 peptides showed high
antigenicity and immunoreactivity. The antisera from peptides
(P6, P8, P9, and P10) immunized rabbits showed good speciﬁc-
ity and high aﬃnity to S protein. It was conﬁrmed that the P8
peptide is the best candidate for usage in SARS serological
diagnosis. After some optimization, the peptide PL8 derived
from P8, revealed a speciﬁc response to SARS speciﬁc IgGblished by Elsevier B.V. All rights reserved.
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in all tested SARS patients.
Neutralization experiments using a syncytia formation
model showed that the peptides P8 and P9 themselves can
markedly inhibit syncytia formation, indicating that the corre-
sponding regions spanning sequences (540–559) and (731–753)
within the S protein may be new targets for eﬃcient SARS
drug development.Fig. 1. Map of peptides used for immunization. The spike protein is
predicted to be cleaved at amino acid 667 and 668 according to
bioinformatics analysis. (A) Full-length S protein, S1 and S2 fragments
were expressed by E. coli and served as target proteins for Western
blot. (B) Eight peptide sequences were selected from the S1 fragment
and two peptide sequences were selected from the S2 fragment.2. Materials and methods
2.1. Peptide design and synthesis
After analyzing the SARS spike protein (gi: 30173397) with software
DNAstar, 10 peptides were selected from the whole sequence of the S
protein based on their indices of antigenicity, hydrophilicity, surface
probability, and ﬂexible region. These peptides were synthesized using
conventional solid-phase chemical methodology and puriﬁed in GL
Bio-Chem (Shanghai) Ltd [8].
2.2. Immunization
Bovine serum albumin (BSA, Sigma) served as a carrier protein for
conjugation with peptides. New Zealand white rabbits (Shanghai Lab-
oratory Animal Center, Chinese Academy of Sciences) were immu-
nized subcutaneously on the back of the rabbits with 200 lg of
diﬀerent BSA-conjugated peptides emulsiﬁed (1/1 v/v) with complete
Freunds adjuvant (CFA). The same amount of peptides dissolved in
incomplete Freunds adjuvant (IFA) was used to boost immunization
in the rabbits on days 21 and 42 following immunization. The antisera
were collected on day 49 following ﬁrst immunization.
2.3. Prokaryotic S protein expression
The recombinant intact S protein, S1 and S2 fragments were ex-
pressed by Escherichia coli and they were puriﬁed by Model 422 Elec-
tro-Eluter (Bio-rad) and subjected to SDS–PAGE analysis [5].
2.4. Preparation of virus lysates
Vero E6 cells were infected with SARS-CoV for 24 h and collected
as previously described [9]. Infected cells were lysed with a solution
containing 40 mM Tris (pH 8.3) and 0.5% Nonident P-40 at 22 C
for 5 min. The virus lysate was centrifuged at 8000 rpm for 5 min,
and then the supernatant was collected and boiled for 5 min. All exper-
iments using virus were carried out in a biosafety level 3 laboratory.
2.5. Western blot
The expressed whole length S protein, S1 and S2 fragments as well as
the native S proteins extracted from the lysate of SARS-CoV infected
Vero E6 cells were used to detect their binding activities with peptide-
induced antisera. Binding Abs were then detected by the second Ab
(HRP-conjugated goat anti-rabbit IgG). ECL-detection reagents
(Amersham Pharmacia Biotech) were used to develop the ﬁlms.
2.6. Serum samples
58 sera of SARS patients and 40 sera of healthy individuals were
used. All of the experiments using both of these sera were carried
out in a biosafety level 3 laboratory. All the conﬁrmed SARS patients
sera were IgG positive when analyzed by ELISA using whole virus ly-
sates.
2.7. ELISA procedure
The reactivity of the peptides to the SARS patients sera was also
measured by ELISA. The 96-well plates were coated with the BSA–
peptide conjugates(5 lg/ml, 50 ll/well) in coating buﬀer (pH 9.4) at
4 C overnight. Afterwards the wells were washed with PBS, and were
blocked with BSA at 37 C for 2 h and then the sera or the puriﬁed IgG
from SARS patients sera was added as the ﬁrst Ab. The sera dilution
was 1:10 and the puriﬁed IgG dilution was 1:1000. Plates were stored
at 37 C for 30 min, then washed again with PBS. After that, HRP-
coupled goat anti-human IgG (Bio-rad) was added, and OD values
were measured with a microplate autoreader (Biotek) at 450 nm.2.8. Syncytia inhibition assay
Syncytia formation was used to mimic the SARS-CoV infection pro-
cedure [10]. In our study, we modiﬁed this assay by introducing lucif-
erase assay in the detecting system (Fig. 5A and B).
The cell fusion-dependent reporter gene (luciferase) activation assay
was adapted to our studies of spike protein-mediated membrane fu-
sion. In brief, eﬀector cells were generated by cotransfection of
HEK293 T cell monolayers (106 cells/60 mm dish) with plasmids
pCDNA3.1-ACE2 and pUHD 15-1(SV40), while target cells (contain-
ing the luciferase reporter gene) were generated by cotransfection of
HEK293 T cell with pCDNA3.1-spike-Ig and pUHD 10-3. Twenty-
four hours after transfection, eﬀector cells and target cells were trypsin-
ized, resuspended in DMEM–10% FBS, then two kinds of cell suspen-
sions were mixed (1:1 cell number) and repelleted.
All the antisera and peptides (20 ll of each antiserum and 125 lM of
each peptide) were added into the cell suspension mixture to investi-
gate their inhibitory capacity. Antiserum or peptide was incubated
with cell suspensions at 23 C for 1 h, and then re-plated into a 48-well
culture plate at 37 C for 24 h. Finally, media were removed and cells
were lysed with 100 ll Passive Lysis Buﬀer (Promega). Luciferase
intensity was measured in a luminometer TD-20/20.3. Results
3.1. Bioinformatics analysis and peptide selection
We predicted that the cleavage site of the SARS-CoV spike
protein containing 1255 residues is located between amino acid
residues 667 and 668 [5]. The fragments of 1–667 and 668–1255
represent S1 and S2, respectively. All peptides are designated
according to four characteristics: antigenicity, surface proba-
bility, hydrophilicity and ﬂexible region. The peptides P1 to
P8 were derived from the S1 fragment and the peptides P9
and P10 were from the S2 fragment (Fig. 1 and Table 1).
3.2. Antigenicities of synthesized peptides were evaluated by
Western blot
In order to test the antigenicity of these synthetic peptides to
immunize rabbits, all of them were coupled with BSA. The
antisera with high titers were collected on day 49 following
immunization. The binding activity and speciﬁcity of Abs were
determined by Western blot with E. coli expressed S1 frag-
ment, S2 fragment and full-length S proteins as well as the na-
tive S protein isolated from the lysates of SARS-CoV infected
Vero-E6 cells. The data demonstrated that anti-P3, P5, P7
antisera bound to S1 and S2 fragments. They also showed
weak and non-speciﬁc binding activities to the lysates of virus
Table 1
Ten peptides were synthesized based on bioinformatics analysis
No. Position Peptide sequence Putative
location
Antigenic
index
Hydrophilicity
plot
Surface probability
plot
Flexible
region
P1 34–54 TSSMRGVYYPDEIFRSDTLYL S1 ++ ++ + +
P2 94–113 KSNVVRGWVFGSTMNNKSQS S1 ++ + + +
P3 197–216 YKGYQPIDVVRDLPSGFNTL S1 ++ + + 
P4 273–293 TDAVDCSQNPLAELKCSVKSF S1 ++ +  +
P5 297–316 KGIYQTSNFRVVPSGDVVRF S1 + +  +
P6 332–351 TKFPSVYAWERKKISNCVAD S1 ++ + + +
P7 436–455 YNYKYRYLRHGKLRPFERDI S1 +++ +++ ++ +
P8 540–559 PSSKRFQPFQQFGRDVSDFT S1 +++ +++ + +
P9 731–753 CANLLLQYGSFCTQLNRALSGIA S2    
P10 758–780 RNTREVFAQVKQMYKTPTLKYFG S2 + ++ ++ +
Fig. 2. Speciﬁcity of the peptide-induced antisera as indicated by
Western blot analysis. Lane 1: recombinant SARS-CoV Spike protein
expressed in E. coli; lane 2: S1 fragment expressed in E. coli; lane 3: S2
fragment; lane 4: SARS-CoV infected Vero E6 cell lysate; lane 5: non-
infected Vero E6 cell lysate. Details are seen in Table 2. Sn, native
spike protein; Se, recombinant S protein expressed in E. coli; S1,
recombinant S1 fragment of S protein expressed in E. coli; S2,
recombinant S2 fragment.
Fig. 3. Immunoreactivities of all peptides (P1–P10). The puriﬁed IgG
from SARS patients sera served as S-protein speciﬁc Ab. BSA was
used as a negative control. The binding activities of the IgG to all 10
peptides derived from S protein were detected by ELISA. The puriﬁed
human IgG of SARS patients were 1:500 dilution and HRP-coupled
anti-human IgG served as second Ab.
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binding speciﬁcity to the S Protein of SARS-CoV. In contrast,
anti-P6, P8, P9 and P10 antisera had speciﬁc binding to the S
fragments and S protein expressed in E. coli and SARS-CoV
infected cell lysates, suggesting that those Abs have a potential
to recognize S protein of SARS-CoV in its natural form (Fig. 2
and Table 2).
3.3. Immunoreactivity of synthesized peptides were evaluated
with IgG puriﬁed from SARS patients sera
To study the immunogenicity of peptides derived from S
protein of SARS-CoV in vivo, the S protein-speciﬁc IgG was
puriﬁed from 10 SARS patients sera and the mixture contain-Table 2
Western blot analysis: the interactions between peptide-speciﬁc antibodies a
Anti-P1 Anti-P2 Anti-P3 Anti-P4 Anti
S protein   + + +
S1 fragment   +  +
S2 fragment  + + + +
Native S protein  + +  +
Negative control    + +
Speciﬁcity     
Note. The S protein, S1 fragment and S2 fragment were isolated from E. co
Native S protein: from the lysates of SARS-CoV infected Vero E6 cell.
Negative control: from the lysates of normal Vero E6 cell.ing IgG served as a template to determine its reaction with the
peptides. Ten peptides showed diﬀerent immunoreactivities to
the puriﬁed IgG, in which the P5, P8 and P9 peptides revealed
relatively higher responses than other peptides (Fig. 3). The P8
peptide with the highest immunoreactivity may contain a po-
tential dominant B cell epitope on the S protein of SARS-CoV.
3.4. The application of P8 peptide in SARS serological diagnosis
Since P8 peptide can react with puriﬁed IgG from SARS pa-
tients sera, we ask whether the P8 peptide could be used as an
antigen for SARS serological diagnosis. To initially address
this possibility, the reactions between P8 and sera from SARS
patients as well as normal individuals were tested by ELISA.
The peptide derived from murine IL-12b2-receptor (IL-12R:
CNRLDLGINLSPDLAESPRFI) served as a negative controlnd diﬀerent kinds of S antigen
-P5 Anti-P6 Anti-P7 Anti-P8 Anti-P9 Anti-P10
+ + + + +
+ + +  
   + +
+ + + + +
 + +/  +
+  + + +
li expressed protein.
Table 3
The immunoreactivity of P8 peptide to the IgG of SARS patients sera was determined by ELISA
Group P8 peptide IL-12R peptide
No. P % No. P %
SARS patients 10 9 90 10 0 0
Health control 6 3 50 6 0 0
Note. No., means number of sera from SARS patients or healthy people; P, the number of positive response; %, reactivity percentage over total tested
sera.
Fig. 4. The extended PL-8 peptide showed higher immunoreactivity
and higher speciﬁcity than P8. (A) The PL-8 had a higher aﬃnity to the
IgG puriﬁed from the sera of SARS patients than that of P8. (B) The
speciﬁcity of peptides to SARS sera was compared between PL8 and
IL-12R peptides. PL8 showed a high speciﬁcity and aﬃnity to SARS
sera, but it did not response to the sera from health control. Fig. 5. Spike protein-ACE2-mediated syncytia formation model. (A)
HEK293T cells were transfected with SARS-CoV spike protein gene
and pUHD15-1 (SV40); while at the same time, other HEK293T cells
were transfected with ACE2 gene and pUHD10-3. The two kinds of
treated cells can fuse with each other and form syncytia, which contain
pUHD15-1 and pUHD10-3 together and induce the reporter gene
expression. (B) The model was tested by a known neutralizing
monoclonal antibody, which was obtained from mice immunized with
S protein integrated pseudo-virus. () group: ACE2 is not transduced
into the HEK293T cells, so no syncytia formation. (+) group: control
IgG Ab was used in the test, resulting in the completed syncytia
formation.
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sera from SARS patients (positive in 9/10 SARS patients).
However, it also had a false positive response to the sera of
normal individuals (positive in 3/6 cases), whereas the control
peptide showed a negative response to sera both from SARS
patients and from uninfected normal individuals (Table 3).
It was likely that a short peptide (about 20 amino acid resi-
dues in length) was not suﬃcient to mimic a speciﬁc B cell epi-
tope within the S protein. In addition to linear B cell epitopes,
the conformational structure in the synthetic peptide might
also be helpful to form the speciﬁc binding site recognized by
its corresponding Ab in vivo.We assumed that extending the peptide longer may be help-
ful to create a speciﬁc binding site. The P8 peptide was
extended to 30 amino acids (Sequence: PSSKRFQPF-
Fig. 6. Neutralization test on S-ACE2 syncytia formation model.
(A) Six antisera from P5 to P10, which have good reaction with S
proteins, were selected to test their inhibition. Only anti-P6 and anti-P8
Abs showed minor inhibition. () group: ACE2 is not transduced into
the HEK293T cells, so no syncytia formation. (+) group: no Ab was
used in the test, result in the completed syncytia formation. a-N group:
antibodies against an irrelative peptide N1 (from N protein of SARS-
CoV) was used in the test as a control. (B) All of the peptides were used
in the test, and peptides P8 and P9 can inhibit the syncytia formation
to nearly 50%. () group: ACE2 was not transduced into the
HEK293T cells, so no syncytia formation; (+) group: no peptide was
used in the test, resulting in complete syncytia formation; (N) group:
an irrelevant peptide N1 (from N protein of SARS-CoV) was used in
the test as a control; no inhibition was observed. (C) Only P8 and P9
peptides were selected to do the test again, and the data demonstrate
the inhibition remarkably. All of the experiments were repeated several
times. () group: ACE2 was not transduced into the HEK293T cells,
so no syncytia formation. (+) group: no peptide was used in the test,
resulting in complete syncytia formation. (N) group: an irrelevant
peptide N1 was used in the test, no inhibition was observed.
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conﬁrm our hypothesis, S protein-speciﬁc IgG was puriﬁed
from the sera of SARS patients. The binding aﬃnity of PL8
and P8 to the IgG was compared by ELISA. As we expected,
PL8 showed higher aﬃnity than that of P8 (Fig. 4A). The re-
sults supported our hypothesis.
To further conﬁrm whether PL8 could be suitable for diag-
nosis of SARS, the sera were obtained from 58 diagnosed
SARS patients and 40 uninfected normal individuals. The
binding speciﬁcity of PL8 to SARS-speciﬁc IgG was measured
by ELISA. In the parallel experiments, 70% of 58 SARS pa-
tients tested were positive. In contrast, only 5% of the normal
healthy individuals tested were positive. (Fig. 4B). The control
peptides, IL-12R, had a very low rate of binding to both sera
from the patients and the uninfected people. It was likely that
the 30 amino acids length peptide might create a conforma-
tional structure within the S protein recognized S protein-spe-
ciﬁc Ab in vivo.3.5. Synthetic peptides suppress interaction between ACE2 and
S protein
A syncytia formation model has been widely used as an as-
say to detect neutralizing activities of Abs and peptides [10].
Initially, to make sure whether our syncytia formation
model works well, we tested the model by using a neutralizing
monoclonal Ab, which was generated in our lab. It is speciﬁc
to S protein (S310–510 fragment) of SARS-CoV and its neu-
tralizing activity had been conﬁrmed in SARS-CoV infected
Vero E6 cells (data not shown). The data demonstrated that
the syncytia formation was inhibited by this Ab (Fig. 5A
and B). The results indicate that the model is suitable for test-
ing the neutralizing activities of Abs or peptides.
Then a potential prevention of SARS infectivity by those
peptides or their corresponding Abs was evaluated with this
model. It is interesting to note that, compared with control
antisera, only a few of the antisera had a minor inﬂuence on
syncytia formation, such as anti-P6, P8, P10 antisera
(Fig. 6A). The results showed that all peptide-induced poly-
clonal Abs were unable to inhibit syncytia formation, suggest-
ing that the tested Abs did not have neutralizing activities.
When PL8-induced antiserum was tested with the model, it
also did not show an inhibition (data not shown).
Recently, there are many reports demonstrating that pep-
tides themselves are a good candidate for anti-virus drug de-
sign [12]. In this study, we also tested all peptide-mediated
inhibition by using the model. It was obvious that the P8
and P9 peptides could signiﬁcantly inhibit syncytia formation
(Fig. 6B and C). The data indicated that the regions spanning
P8 and P9 peptide sequences within the S protein might repre-
sent a new target for drug development.4. Discussion
SARS-CoV spike protein is an essential structural protein in
the virus life span. It has an important function in SARS path-
ogenesis [13]. It not only plays an important role in viral infec-
tion, but it also is a potential drug target. In this study, we
probed for the B cell epitopes on the S protein by bioinformat-
ics analysis and peptide immunization in vivo, and explored
their potential usage in disease diagnosis and treatment.
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and epitope prediction score, according to bioinformatics anal-
ysis, only a few of them could induce a strong and speciﬁc im-
mune response. Our data suggested that the AI for peptides
was not a crucial factor, in fact, the ﬂexible region, hydrophi-
licity and surface probability were also important factors for
epitope prediction.
In order to test the bioinformatics analysis results, a series of
experiments were performed. To conﬁrm that these peptides
contain relevant B cell epitopes within the S protein of the
SARS-CoV, the native S protein from the lysates of SARS-
CoV infected Vero E6 cells and puriﬁed S protein-speciﬁc
IgG from SARS patients were used to determine their antige-
nicity and immunoreactivity. The data demonstrate that the P8
spanning region contains a good B cell epitope on S protein
and that it has the potential for application in SARS diagnosis.
Unexpectedly, the P8 peptide was highly antigenic, but had
some cross reactivity with sera obtained from uninfected
normal individuals. Its sequence analysis showed that small
fragments of 6–8aa in length of the P8 peptide (PSSKRFQ-
PFQQFGRDVSDFT) shared homology with other pathogens
and human tissue antigens. One report demonstrated that a
bootscan recombination analysis of the spike gene revealed
high nucleotide identity between the SARS virus and a feline
infectious peritonitis virus throughout the gene, except for a
200-base-pair region of high identity to an avian sequence,
indicating a mammalian-avian mosaic origin for the host-
determining spike protein [14]. Furthermore, in our experi-
ments, P8 also had a higher cross reactivity with sera from
autoimmune disease patients, such as SLE (data not shown).
Our results suggest that the P8 peptide has homologies either
to normal tissue antigens or to other pathogens which were
contacted by uninfected normal individuals during their life-
time. This may account for the cross reaction.
Then we attempted to optimize the P8 peptide by extending
its length by adding a 10aa length fragment at its C terminal.
The obtained peptide PL8 had a speciﬁc response rate of 70%
in SARS patients whereas the false positive rate was below 5%
in uninfected normal individuals (2/40). It is possible that the
longer PL8 can form a conformational B cell epitope, which
is more speciﬁc and immunogenic than the shorter P8. Our
data conﬁrm this hypothesis.
Currently there are many diagnostic methods for SARS
detection, such as real time RT-PCR and ELISA with virus ly-
sates as an antigen. RT-PCR is too expensive to be applied in
small hospitals, and its use was limited in a clinical setting due
to diﬃculties in sample collection and low levels of accuracy
[15]. ELISA is a simple and convenient method to detect
SARS, but a diagnostic kit for SARS-CoV is not available.
Currently, some methods, such as those employing lysates of
virus infected Vero E6 cells as antigen, could be used for SARS
diagnosis, but their speciﬁcity is not adequate and safety is a
concern, too. The peptide-based SARS ELISA test has some
advantages. This test is much cheaper and quicker than others,
such as RT-PCR. The peptide is easy and safe to prepare as
compared to whole virus lysates. It is conceivable that the test
can be optimized by using more than one peptide which often
will improve the sensitivity and reliability of a diagnostic test.
In this study, we demonstrated that PL8 is a good candidate
for usage in serological diagnosis of SARS.
Synthetic peptides are also useful to develop eﬃcient SARS
therapeutic drugs. For example, peptide immunization cangenerate speciﬁc Abs [16–18]. If a peptide containing a neutral-
izing epitope, which can inhibit the interaction between virus
spike protein and its ACE2 receptor. The epitope can be used
for generating an eﬀective neutralizing Ab or for vaccination.
The peptide itself can also be used as an agent to inhibit virus
infection, if it can provide a spatial block between S protein
and ACE2 [12].
The spike protein-ACE2 syncytia formation model mimics
the SARS-CoV infection processes and this model can be
safely used in a laboratory. Some antisera, peptides or small
chemical molecules can be selected to screen their neutralizing
ability by using this model.
In this study, we successfully identiﬁed four B cell epitopes on
the spike protein of SARS-CoV, but they did not show a neu-
tralizing activity. However, when all the peptides were tested
for their neutralization ability, P8 and P9 peptides signiﬁcantly
inhibited syncytia formation. When their sequences were com-
pared, P8 (540 PSSKRFQPFQQFGRDVSDFT 559) and P9
(731CANLLLQYGSFCTQLNRA LSGIA 753) did not show
any special characteristics. The two peptides spanning se-
quences within the S protein are diﬀerent from the ACE2 bind-
ing site (from S318 to 510) or the fusion motif (S889-972 and
S1142-1185) [12,19]. Our data indicate that the two regions
(P8 and P9) from S protein may contain a crucial new drug tar-
get, but the actual mechanism of the inhibition is unclear.
In summary, bioinformatics analysis and peptide immuniza-
tion in vivo are essential to identify B cell epitopes on a given
antigen, such as SARS-CoV spike protein. PL8 represents an
immunogenic peptide sequence from S protein, which has a
potential to be used in SARS diagnosis. The neutralization
ability of P8 and P9 peptides indicates that the respective re-
gions of the S protein may contain a new target for anti-SARS
drug development.
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